These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

340 related articles for article (PubMed ID: 32314509)

  • 1. Comprehensive analysis of serum chromogranin A and neuron-specific enolase levels in localized and castration-resistant prostate cancer.
    Szarvas T; Csizmarik A; Fazekas T; Hüttl A; Nyirády P; Hadaschik B; Grünwald V; Püllen L; Jurányi Z; Kocsis Z; Shariat SF; Sevcenco S; Maj-Hes A; Kramer G
    BJU Int; 2021 Jan; 127(1):44-55. PubMed ID: 32314509
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The prognostic value of serum MMP-7 levels in prostate cancer patients who received docetaxel, abiraterone, or enzalutamide therapy.
    Szarvas T; Csizmarik A; Váradi M; Fazekas T; Hüttl A; Nyirády P; Hadaschik B; Grünwald V; Tschirdewahn S; Shariat SF; Sevcenco S; Maj-Hes A; Kramer G
    Urol Oncol; 2021 May; 39(5):296.e11-296.e19. PubMed ID: 33046366
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Chromogranin A and neurone-specific enolase variations during the first 3 months of abiraterone therapy predict outcomes in patients with metastatic castration-resistant prostate cancer.
    Fan L; Wang Y; Chi C; Pan J; Xun S; Xin Z; Hu J; Zhou L; Dong B; Xue W
    BJU Int; 2017 Aug; 120(2):226-232. PubMed ID: 28107595
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Chromogranin A and neurone-specific enolase serum levels as predictors of treatment outcome in patients with metastatic castration-resistant prostate cancer undergoing abiraterone therapy.
    Heck MM; Thaler MA; Schmid SC; Seitz AK; Tauber R; Kübler H; Maurer T; Thalgott M; Hatzichristodoulou G; Höppner M; Nawroth R; Luppa PB; Gschwend JE; Retz M
    BJU Int; 2017 Jan; 119(1):30-37. PubMed ID: 27037533
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Influence of abiraterone acetate on circulating neuromediators in chemotherapy-naïve castration-resistant prostate cancer.
    von Hardenberg J; Schwartz M; Werner T; Fuxius S; Müller M; Bolenz C; Weiß C; Heinrich E
    Prostate; 2016 May; 76(7):613-9. PubMed ID: 26779767
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prospective Evaluation of Neuromediator Dynamics in Castration-Resistant Prostate Cancer Patients During Docetaxel.
    VON Hardenberg J; Schwartz M; Werner T; Fuxius S; Müller M; Frangenheim T; Bolenz C; Weiss C; Heinrich E
    Anticancer Res; 2017 Sep; 37(9):5117-5124. PubMed ID: 28870943
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Influence of abiraterone acetate on neuroendocrine differentiation in chemotherapy-naive metastatic castration-resistant prostate cancer.
    Dong B; Fan L; Wang Y; Chi C; Ma X; Wang R; Cai W; Shao X; Pan J; Zhu Y; Shangguan X; Xin Z; Hu J; Xie S; Kang X; Zhou L; Xue W
    Prostate; 2017 May; 77(13):1373-1380. PubMed ID: 28804908
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Abiraterone Followed by Enzalutamide Versus Enzalutamide Followed by Abiraterone in Chemotherapy-naive Patients With Metastatic Castration-resistant Prostate Cancer.
    Matsubara N; Yamada Y; Tabata KI; Satoh T; Kamiya N; Suzuki H; Kawahara T; Uemura H; Yano A; Kawakami S; Otsuka M; Fukasawa S
    Clin Genitourin Cancer; 2018 Apr; 16(2):142-148. PubMed ID: 29042308
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment of Metastatic Castration-resistant Prostate Cancer With Abiraterone and Enzalutamide Despite PSA Progression.
    Becker DJ; Iyengar AD; Punekar SR; Ng J; Zaman A; Loeb S; Becker KD; Makarov D
    Anticancer Res; 2019 May; 39(5):2467-2473. PubMed ID: 31092441
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Somatostatin analogs and disease control in castration-resistant prostate cancer: different biological behavior? Case series and review of the literature.
    D'Angelillo RM; Greco C; Fiore M; Ippolito E; Eolo Trodella L; Iurato A; Molfese E; Ramella S; Trodella L
    Tumori; 2014; 100(3):249-53. PubMed ID: 25076233
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Chromogranin A is a potential prognostic marker in prostate cancer patients treated with enzalutamide.
    Conteduca V; Burgio SL; Menna C; Carretta E; Rossi L; Bianchi E; Masini C; Amadori D; De Giorgi U
    Prostate; 2014 Dec; 74(16):1691-6. PubMed ID: 25262981
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The New Combination Docetaxel, Prednisone and Curcumin in Patients with Castration-Resistant Prostate Cancer: A Pilot Phase II Study.
    Mahammedi H; Planchat E; Pouget M; Durando X; Curé H; Guy L; Van-Praagh I; Savareux L; Atger M; Bayet-Robert M; Gadea E; Abrial C; Thivat E; Chollet P; Eymard JC
    Oncology; 2016; 90(2):69-78. PubMed ID: 26771576
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Chromogranin A predicts outcome in prostate cancer patients treated with abiraterone.
    Burgio SL; Conteduca V; Menna C; Carretta E; Rossi L; Bianchi E; Kopf B; Fabbri F; Amadori D; De Giorgi U
    Endocr Relat Cancer; 2014 Jun; 21(3):487-93. PubMed ID: 24741024
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Influence of abiraterone and enzalutamide on body composition in patients with metastatic castration resistant prostate cancer.
    Fischer S; Clements S; McWilliam A; Green A; Descamps T; Oing C; Gillessen S
    Cancer Treat Res Commun; 2020; 25():100256. PubMed ID: 33307509
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Serum Neuroendocrine Markers Predict Therapy Outcome of Patients with Metastatic Castration-Resistant Prostate Cancer: A Meta-Analysis.
    Liu Y; Zhao S; Wang J; Zhu Z; Luo L; Li E; Tang F; Zhao Z
    Urol Int; 2019; 102(4):373-384. PubMed ID: 30517936
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Neuroendocrine differentiation in stage D2 prostate cancers.
    Kamiya N; Suzuki H; Kawamura K; Imamoto T; Naya Y; Tochigi N; Kakuta Y; Yamaguchi K; Ishikura H; Ichikawa T
    Int J Urol; 2008 May; 15(5):423-8. PubMed ID: 18452460
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic value of neuroendocrine serum markers and PSA in irradiated patients with pN0 localized prostate cancer.
    Lilleby W; Paus E; Skovlund E; Fosså SD
    Prostate; 2001 Feb; 46(2):126-33. PubMed ID: 11170140
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treating Patients with Metastatic Castration Resistant Prostate Cancer: A Comprehensive Review of Available Therapies.
    Crawford ED; Higano CS; Shore ND; Hussain M; Petrylak DP
    J Urol; 2015 Dec; 194(6):1537-47. PubMed ID: 26196735
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The chromogranin-A (CgA) in prostate cancer.
    Ranno S; Motta M; Rampello E; Risino C; Bennati E; Malaguarnera M
    Arch Gerontol Geriatr; 2006; 43(1):117-26. PubMed ID: 16280180
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Proteome profiling of enzalutamide-resistant cell lines and serum analysis identified ALCAM as marker of resistance in castration-resistant prostate cancer.
    Csizmarik A; Keresztes D; Nagy N; Bracht T; Sitek B; Witzke K; Puhr M; Tornyi I; Lázár J; Takács L; Kramer G; Sevcenco S; Maj-Hes A; Jurányi Z; Hadaschik B; Nyirády P; Szarvas T
    Int J Cancer; 2022 Oct; 151(8):1405-1419. PubMed ID: 35689436
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.